New recommendations issued for use of cetuximab in colon cancer therapy

Jul 16, 2010

In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed.

Based on earlier studies, cetuximab is now indicated for treatment of patients with advanced whose tumors do not have a mutation in the KRAS gene. KRAS is one of a series of genes along a pathway that can lead tumors cells to grow, divide and evade signals that shut the cells down causing their death. Based on the results in advanced disease, researchers had hoped to see similar benefits when cetuximab was added to a standard chemotherapy regimen in earlier stages of colon cancer. However, ongoing analysis during the clinical trial found that patients receiving the combination therapy had no significant improvement in survival compared to standard therapy.

Cetuximab is a monoclonal antibody that inhibits epidermal (EGFR) - a cell signaling pathway that contributes to . The drug is given by intravenous infusion for treatment of metastatic colorectal cancer and . Previously, researchers found that patients with a mutated KRAS gene - about 40 percent of those with metastatic colon cancer - do not respond to the EGFR inhibitors currently in use.

However, the genetic test for KRAS mutation was not standard until this trial was well underway. Patients enrolled before KRAS testing were segmented from those in the rest of the study and analyzed separately, said Richard Goldberg, MD, chief of the division of hematology/oncology at the UNC-Chapel Hill School of Medicine, who presented the results for this group of patients.

"We expected that patients with the genetic mutation would not respond to cetuximab, and that is what we found," said Goldberg, who is also physician-in-chief of the N.C. Cancer Hospital.

"However, even the patients in the study whose tumors did not harbor the KRAS mutation did not benefit significantly from the combination therapy and the standard treatment proved to have the best results. We also found that the was more toxic and the side effects of treatment - especially in older patients - negatively impacted their ability to complete the standard treatment," he added.

The researchers issued a recommendation that should not be used in patients with stage III . It remains a valuable tool in treating patients with advanced colorectal cancers whose tumors do not harbor a KRAS mutation and can either be administered as a single agent or with chemotherapy.

Explore further: 20 years of data shows treatment technique improvement for advanced abdominal cancer

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Unraveling the 'black ribbon' around lung cancer

3 hours ago

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

Survival hope for melanoma patients thanks to new vaccine

8 hours ago

(Medical Xpress)—University of Adelaide researchers have discovered that a new trial vaccine offers the most promising treatment to date for melanoma that has spread, with increased patient survival rates and improved ability ...

User comments : 0

More news stories

Turning off depression in the brain

Scientists have traced vulnerability to depression-like behaviors in mice to out-of-balance electrical activity inside neurons of the brain's reward circuit and experimentally reversed it – but there's ...

Spate of Mideast virus infections raises concerns

A recent spate of infections from a frequently deadly Middle East virus is raising new worries about efforts to contain the illness, with infectious disease experts urging greater vigilance in combatting ...

Clean air: Fewer sources for self-cleaning

Up to now, HONO, also known as nitrous acid, was considered one of the most important sources of hydroxyl radicals (OH), which are regarded as the detergent of the atmosphere, allowing the air to clean itself. ...

Thinnest feasible nano-membrane produced

A new nano-membrane made out of the 'super material' graphene is extremely light and breathable. Not only can this open the door to a new generation of functional waterproof clothing, but also to ultra-rapid filtration. The ...

There's something ancient in the icebox

Glaciers are commonly thought to work like a belt sander. As they move over the land they scrape off everything—vegetation, soil, and even the top layer of bedrock. So scientists were greatly surprised ...